Anthony Brand
Optometrist · Overland Park, KSNPI 1851730931
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 195 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 10.4% — the pattern of someone who eats at a lot of different presentations. Among optometrist clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 195 payments — averaging $25.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$512
- Mallinckrodt Hospital Products Inc.$511
- AbbVie$475
- Bausch & Lomb Americas Inc.$392
- Novartis$365
- Glaukos Corporation$336
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,81798%
- Education$982%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 23 | $512 |
| Mallinckrodt Hospital Products Inc. | 20 | $511 |
| AbbVie(2 entities) | 17 | $475 |
| Bausch & Lomb Americas Inc. | 17 | $392 |
| Novartis | 14 | $365 |
| Glaukos Corporation | 9 | $336 |
| Oyster Point Pharma, Inc. | 12 | $269 |
| Dompe US, Inc. | 10 | $254 |
| Alcon | 13 | $252 |
| Sight Sciences, Inc. | 2 | $163 |
| Rxsight Inc | 3 | $126 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $112 |
| Kala Pharmaceuticals, Inc. | 5 | $109 |
| Genentech USA, Inc. | 4 | $103 |
| Sandoz | 3 | $97 |
| Biotissue Holdings Inc. | 5 | $93 |
| Coherus Oncology, Inc. | 3 | $84 |
| Tarsus Pharmaceuticals, Inc. | 3 | $82 |
| Harrow Eye, LLC | 3 | $79 |
| ANI Pharmaceuticals, Inc. | 3 | $77 |
| Apellis Pharmaceuticals, Inc. | 3 | $68 |
| Biogen | 2 | $50 |
| Thea Pharma Inc. | 2 | $48 |
| Regeneron Healthcare Solutions, Inc. | 2 | $47 |
| Astellas Pharma US Inc | 2 | $43 |
| Shire North American Group Inc | 2 | $28 |
| Alimera Sciences, Inc. | 1 | $25 |
| Notal Vision, Inc. | 1 | $23 |
| Sanofi | 1 | $23 |
| Amgen | 1 | $21 |
| Ocular Therapeutix, Inc. | 1 | $19 |
| Aerie Pharmaceuticals, Inc. | 1 | $17 |
| Eyepoint US, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIIDRA$220
- OMNI(R) SURGICAL SYSTEM (US)$148
- DURYSTA$124
- RESTASIS$116
- MIEBO$101
How this compares
$4,915 in reported general payments places this provider in the 95th percentile of 567 optometrist providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 56 | $70,244 |
| XiidraLifitegrast | 24 | $37,435 |
| Cyclosporine | 45 | $28,410 |
| TyrvayaVarenicline Tartrate | 19 | $27,795 |
| CequaCyclosporine | 15 | $23,960 |
| Loteprednol Etabonate | 92 | $12,191 |
| LumiganBimatoprost | 26 | $10,845 |
| Travoprost | 37 | $9,267 |
| Alphagan PBrimonidine Tartrate | 16 | $7,495 |
| Fluorometholone | 44 | $4,090 |
| Prednisolone Acetate | 132 | $3,825 |
| Latanoprost | 257 | $3,279 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 14 | $2,963 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 111 | $2,548 |
| Difluprednate | 19 | $1,861 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P | $475 | $88,58598 claims |
| Bausch & Lomb Americas Inc.Xiidra | $392 | $37,43524 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $269 | $27,79519 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $512 | $23,96015 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $112 | $12,19192 claims |
| AlconSimbrinza | $252 | $2,96314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 567 optometrist providers in Kansas.
Other optometrist in Overland Park
- Vincent PennipedeOverland Park$16K
- Mark SiefkesOverland Park$11K
- Katherine PainterOverland Park$7K
- Jared JaynesOverland Park$5K
- Jay BurlingameOverland Park$5K
- Neal EylarOverland Park$5K
- Dawn BircherOverland Park$4K
- Liron BittanOverland Park$4K
- L BeslerOverland Park$4K
- Buffie MockOverland Park$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.